A Clover Health Director Sold Over 67,000 Company Shares. Here's a Closer Look at the Transaction.

Director Carladenise Edwards sold 67,160 shares for a transaction value of approximately ~$230,000 on May 18, 2026, at a weighted average price of around $3.42 per share. This sale represented 19% of her direct holdings at the time, reducing direct ownership from 352,592 to 285,432 shares.

The Motley Fool • 5 hours ago

Clover Health Stock Extends Gains After Court Forces CMS to Upgrade Medicare Star Rating

Clover Health Investments Corp. (NASDAQ:CLOV) shares are extending yesterday's 18.9% surge Thursday, after a court-ordered Medicare Star Rating upgrade jumped its PPO plan from 3.5 to 4.5 Stars.

Benzinga • Jun 11, 2026

A Clover Health Insider Sold Over 220,000 Company Shares. What Does That Mean for Investors?

Conrad Wai sold 220,426 shares for a transaction value of ~$879,000, based on the $3.99 per share price reported for May 28, 2026. All shares sold were held in a family trust, with no change to direct ownership.

The Motley Fool • Jun 5, 2026

Jim Cramer Won't Recommend Mortgage Stocks Because 'I Never Know What They Really Own' — But He Loves Intel's 'Burgeoning Packaging Division'

On CNBC's “Mad Money Lightning Round,” Jim Cramer said that the quarterly results released by Clover Health Investments Corp (NASDAQ:CLOV) were "not good." Due to the lackluster results, investors would need to be in "pure spec mode," he added.

Benzinga • Jun 1, 2026

Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises

CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.

Zacks Investment Research • May 7, 2026

Clover Health Reports First Quarter 2026 Results

Business Highlights: Delivered positive GAAP Net Income in the first quarter of 2026, with strong performance across key metrics: Total revenues, Adjusted EBITDA, and Consolidated Gross Profit Market-leading Medicare Advantage membership growth with underlying trends tracking in line with expectations Expect to meet or exceed full year 2026 outlook across all metrics, including achieving first full year GAAP Net Income profitability Financial Results: First quarter 2026 GAAP Net Income of $27 million, an improvement of $29 million year-over-year First quarter 2026 Medicare Advantage membership of 155,773, up 51% year-over-year, and Total revenues of $749 million, up 62% year-over-year First quarter 2026 Consolidated Gross Profit of $160 million, up 47% year-over-year, and Adjusted EBITDA of $40 million, up 56% year-over-year Full Year 2026 Guidance: Average Medicare Advantage membership of 154,000 - 158,000, representing 46% growth year-over-year at the midpoint Total revenues between $2.81 billion and $2.92 billion, representing 49% growth year-over-year at the midpoint Consolidated Gross Profit between $470 million and $510 million, representing 38% growth year-over-year at the midpoint Adjusted EBITDA profitability between $50 million and $70 million GAAP Net Income between $0 million and $20 million WILMINGTON, Del., May 06, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the first quarter 2026.

GlobeNewsWire • May 6, 2026

Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.07 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.05 per share a year ago.

Zacks Investment Research • May 6, 2026

Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates

Butterfly Network, Inc. (BFLY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.06 per share a year ago.

Zacks Investment Research • Apr 30, 2026

Here's Why You Should Retain Clover Stock in Your Portfolio for Now

CLOV rides strong membership growth and an AI-driven care model, but rising costs and policy risks cloud the near-term outlook.

Zacks Investment Research • Apr 9, 2026